DelveInsight has launched a new report on “Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2032”. 

DelveInsight’s “Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pediatric Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Pediatric Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Pediatric Growth Hormone Deficiency Market Report: 

• The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric patients aged one year and older who weigh at least 11.5 kg and have growth failure as a result of insufficient endogenous growth hormone secretion 
• As per the study by Walter et al., the prevalence of GHD ranges between 1:3500 and 1:8700 in Germany
• As per the National Institute for Health and Clinical Excellence (NICE), the prevalence of growth hormone deficiency was estimated to be between 1 in 3500 and 1 in 4000 children 
• In about half of the children with growth hormone deficiency (50%), the cause is unknown (idiopathic growth hormone deficiency) 

Request a sample for the Report: https://www.delveinsight.com/sample-request/pediatric-growth-hormone-deficiency-market

Key benefits of the report:

1. Pediatric Growth Hormone Deficiency market report covers a descriptive overview and comprehensive insight of the Pediatric Growth Hormone Deficiency Epidemiology and Pediatric Growth Hormone Deficiency  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Pediatric Growth Hormone Deficiency market report provides insights on the current and emerging therapies.
3. Pediatric Growth Hormone Deficiency market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Pediatric Growth Hormone Deficiency market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pediatric Growth Hormone Deficiency market. 

Got queries? Click here to know more about the Pediatric Growth Hormone Deficiency Market Landscape 

Pediatric Growth Hormone Deficiency Overview: 

One of the various development problems that a kid may be born with or develop over time is growth hormone deficiency (GHD). It can happen by itself or along with widespread hypopituitarism. Although isolated GHD is typically idiopathic, roughly 25% of individuals have a known cause. Congenital reasons include specific CNS anomalies, abnormalities of the GH-releasing hormone receptor, and abnormalities of the GH1 gene. Acquired causes include meningitis, histiocytosis, brain damage, and therapeutic radiation of the CNS (high-dose radiation can result in global hypopituitarism). The development potential of the vertebrae may be further hampered by radiation to the spine, either preventatively or therapeutically, endangering height gain. 

When the pituitary gland does not produce enough growth hormone, it results in paediatric growth hormone deficiency (PGHD). Damage to either the pituitary gland or the hypothalamus, another gland, may be the reason for it. The harm may develop congenitally, during labour, or after delivery (acquired). PGHD may be congenital (present from birth), acquired (due to brain tumours, head injuries, or other conditions), iatrogenic (caused by cancer therapy), or idiopathic (of unknown cause). 

Pediatric Growth Hormone Deficiency Symptoms:

The symptoms of Pediatric Growth Hormone Deficiency include –

• A younger-looking face
• A chubby body build
• Impaired hair growth
• Delayed puberty

Pediatric Growth Hormone Deficiency Market  

The dynamics of the Pediatric Growth Hormone Deficiency market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as TJ101, NordiFlex, and others during the forecasted period 2019-2032. 

Learn more by requesting for sample @Pediatric Growth Hormone Deficiency Market Landscape  

Pediatric Growth Hormone Deficiency Pipeline Therapies: 

• TJ101
• NordiFlex
• Somavaratan
• MOD-4023 

Pediatric Growth Hormone Deficiency Pipeline Key Companies:

• OPKO Health
• Lumos Pharma
• Versartis Inc. 
• I-Mab Biopharma Co. Ltd.

Table of Contents

1. Pediatric Growth Hormone Deficiency Market Report Introduction

2. Executive Summary

3. SWOT analysis

4. Pediatric Growth Hormone Deficiency Patient Share (%) Overview at a Glance

5. Pediatric Growth Hormone Deficiency Market Overview at a Glance

6. Pediatric Growth Hormone Deficiency Disease Background and Overview

7. Pediatric Growth Hormone Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Pediatric Growth Hormone Deficiency 

9. Pediatric Growth Hormone Deficiency Current Treatment and Medical Practices

10. Pediatric Growth Hormone Deficiency Unmet Needs

11. Pediatric Growth Hormone Deficiency Emerging Therapies

12. Pediatric Growth Hormone Deficiency Market Outlook

13. Country-Wise Pediatric Growth Hormone Deficiency Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Pediatric Growth Hormone Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

Click here to read more about Pediatric Growth Hormone Deficiency Market Outlook 2032 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com